Results 281 to 290 of about 1,254,012 (356)

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

, 2017
Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Antonio Palumbo, Jesús F. San Miguel, Ofer Shpilberg, Kenneth C. Anderson, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Eric Bleickardt, Valerie Poulart, Jennifer Sheng, Oumar Sy, Jessica Katz, Anil Singhal, Paul G. Richardson   +22 more
openalex   +1 more source

The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential

Aging and Cancer, EarlyView.
As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley   +1 more source

A CT-based radiomics model for predicting progression-free survival in patients with epithelial ovarian cancer. [PDF]

BMC Cancer
Leng Y, Zhou J, Liu W, Luo F, Peng F, Gong L.   +5 more
europepmc   +1 more source

Figure 3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study

Ruiliang Wang, Jing Xu, Chenyi Zhu, Wujianhong Liu, Chengqi Jin, Wentao Luo, Tingting Zhao, Changcheng Guo, Wei Chen, Bin Yang   +9 more
openalex   +1 more source

NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT/GPX4‐Regulated Ferroptosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose This study investigates NR4A1's paradoxical roles in glioblastoma (GBM) progression, focusing on its mechanistic link to ferroptosis regulation. We aimed to resolve conflicting reports of NR4A1 as both an oncogene and a tumor suppressor by defining its transcriptional control over xCT/GPX4‐mediated iron homeostasis and its clinical ...
Peng Tao, Shikuan Din, Zhengkang Fu, Qian Sun, Xiwei Zhu, Yuxin Wei, Huan Qu, Xinyi Zhang, Jiaxuan Liu, Chuhua Fu, Qianxue Chen   +10 more
wiley   +1 more source

Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and <i>SMAD4</i> as a predictor of progression-free survival. [PDF]

J Gastrointest Oncol
Elhariri A, Patel J, Mahadevia H, Modi K, Albelal D, Majeed U, Jones JC, Borad MJ, Tran NH, Rutenberg MS, Babiker H.   +10 more
europepmc   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy. [PDF]

Sci Rep
Singh A, Horng H, Roshkovan L, Hershman M, Cohen EA, Aggarwal C, Carpenter EL, Katz SI, Kontos D.   +8 more
europepmc   +1 more source

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Gloria Juan‐Carpena, Natividad Martínez-Banaclocha, Juan Carlos Palazón Cabanes, María Niveiro-de Jaime, Isabel Betlloch Más, Mar Blanes‐Martínez   +5 more
openalex   +2 more sources

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source